share_log

BTIG Downgrades Integra Lifesciences to Sell, Announces $22 Price Target

Benzinga ·  Jul 30 17:49  · Ratings

BTIG analyst Ryan Zimmerman downgrades Integra Lifesciences (NASDAQ:IART) from Neutral to Sell and announces $22 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment